ライフサイエンスコーパス: left atrial

1 the correlation of CF with impedance during left atrial 3-dimensional electroanatomical mapping and

2 ce of stroke occurred in those with baseline left atrial abnormality (incidence rate per 1,000 person

3 We found an association between ECG-defined left atrial abnormality and subsequent nonlacunar ischem

4 th nonlacunar stroke, given that we expected left atrial abnormality to reflect the risk of thromboem

5 d for potential confounders and incident AF, left atrial abnormality was associated with incident isc

6 Left atrial abnormality was defined as PTFV1 >4,000muV*m

7 V1 , an electrocardiographic (ECG) marker of left atrial abnormality, and incident ischemic stroke su

8 We tested percutaneous transthoracic left atrial access in 12 animals (10 pigs and 2 sheep) u

9 Percutaneous transthoracic left atrial access is feasible without instrumenting the

10 LGE imaging and left atrial activation mapping were performed during sin

11 ngs add to the hypothesis that the posterior left atrial adipose tissue mass contributes to structura

12 Posterior left atrial adipose tissue mass is significantly larger

13 The posterior left atrial adipose tissue mass was quantified on comput

14 ry disease), each gram increase of posterior left atrial adipose tissue was associated with 1.32 odds

15 Left atrial AF complexity (4.8 +/- 0.8 fibrillation wave

16 No single left atrial anatomic, functional, or clinical feature wi

17 Systems biology and multifeature profiles of left atrial anatomy and physiology should be used to ass

18 e provides a state-of-the-art perspective of left atrial anatomy and physiology.

19 yzed according to 11 predefined areas in the left atrial and 6 segments around the ipsilateral pulmon

20 ESI >3.7 g/day was associated with larger left atrial and left ventricular dimensions (p < 0.05).

21 AIT improved o2peak, left atrial and ventricular ejection fraction, quality-o

22 nificant improvement in AF symptoms, o2peak, left atrial and ventricular function, lipid levels, and

23 Procedural, left atrial, and fluoroscopy time were reduced by -5%, -

24 and larger ablative lesions were seen in the left atrial antrum using 28-mm cryoballoon.

25 but showed narrower ablative lesions in the left atrial antrum.

26 Randomized trials of left atrial appendage (LAA) closure with the Watchman de

27 er the empirical electrical isolation of the left atrial appendage (LAA) could improve success at fol

28 Left atrial appendage (LAA) electric isolation is report

29 the characterization of left atrial (LA) and left atrial appendage (LAA) flow dynamics in patients wi

30 The left atrial appendage (LAA) has been identified as a pre

31 Prophylactic exclusion of the left atrial appendage (LAA) is often performed during ca

32 Electric left atrial appendage (LAA) isolation (LAAI) may occur d

33 Transcatheter left atrial appendage (LAA) ligation may represent an al

34 Left atrial appendage (LAA) ligation with the Lariat dev

35 with nonvalvular atrial fibrillation (NVAF), left atrial appendage (LAA) occlusion was noninferior to

36 Left atrial appendage (LAA) procedures have been develop

37 l as premature atrial contractions, from the left atrial appendage at a coupling interval of 200 ms i

38 Left atrial appendage closure (LAAC) and nonwarfarin ora

39 dy sought to assess composite data regarding left atrial appendage closure (LAAC) in 2 randomized tri

40 The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic the

41 Left atrial appendage closure (LAAC) was approved by the

42 Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) with the Watchman d

43 Safety data on percutaneous left atrial appendage closure arises from centers with c

44 The implantation of left atrial appendage closure device (WATCHMAN, Boston S

45 an updated overview of current transcatheter left atrial appendage closure devices and review the res

46 Over the past decade, percutaneous left atrial appendage closure has emerged as a valid alt

47 dverse outcomes associated with percutaneous left atrial appendage closure is higher in the real-worl

48 f adverse outcomes and costs of percutaneous left atrial appendage closure procedure in the US.

49 In the PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Pro

50 Left atrial appendage closure with the device (n = 463)

51 vices and review the results associated with left atrial appendage closure, focusing on procedural an

52 During left atrial appendage closure, the estimated dose absorb

53 In the study, we performed left atrial appendage closure.

54 rm follow-up continues to support a role for left atrial appendage exclusion from the central circula

55 In this setting, thrombus in the left atrial appendage has been found to be the source of

56 tting typically results from thrombus in the left atrial appendage has led to the development of mech

57 AF the intramyocardial blood vessels of the left atrial appendage have an increased CML presence and

58 significantly higher in blood vessels of the left atrial appendage in AF patients as compared to cont

59 mly assigned to undergo empirical electrical left atrial appendage isolation along with extensive abl

60 ng the effectiveness of empirical electrical left atrial appendage isolation for the treatment of LSP

61 (Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure O

62 ring repeat procedures, empirical electrical left atrial appendage isolation was performed in all pat

63 ups were novel oral anticoagulants, Watchman left atrial appendage occlusion device (DEVICE), and war

64 of stroke, site-specific therapy directed at left atrial appendage occlusion has been now studied for

65 fibrosis on conduction velocity (CV) in the left atrial appendage of patients with AF.

66 X2c RNAs were highly correlated in 233 human left atrial appendage samples.

67 ) of follow-up from the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in P

68 rawn predominantly from PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in P

69 The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in P

70 Left atrial appendage tissue from 33 AF patients and 9 c

71 ar) follow-up of Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Preven

72 tral annulus along the posterior base of the left atrial appendage visualized by selective angiograph

73 ctural parameters of the left atrium and the left atrial appendage which have been shown to be associ

74 Myofibroblasts were not detected in the left atrial appendage.

75 All patients underwent closure of the left atrial appendage.

76 al ligament disruption, and exclusion of the left atrial appendage.

77 CACs and CSCs were cultured from left atrial appendages and blood samples obtained from p

78 Left atrial appendages from 239 patients stratified by c

79 g were performed on DNA from lymphocytes and left atrial appendages of 34 patients (25 with AF).

80 Thirty-five left atrial appendages were obtained during AF surgery.

81 CVL was higher in left atrial appendages with thick compared with thin int

82 itus had a greater left ventricular mass and left atrial area than patients without diabetes mellitus

83 c AF (66% paroxysmal AF; age, 58+/-10 years; left atrial area, 27+/-7 cm(2)) underwent preprocedure C

84 adjustments for left ventricular mass index, left atrial area, and interim heart failure events parti

85 inus activation, and 13 other macroreentrant left atrial ATs.

86 ial LGE signal intensity divided by the mean left atrial blood pool intensity was calculated for each

87 s were analyzed using left ventricle cavity, left atrial cavity, or inferior vena cava as the IDIF.

88 We sought to examine the association between left atrial conduction velocity and LGE in patients with

89 tude, consistent with its positive impact on left atrial contraction.

90 -up of 976.5 days between patients with LAE (left atrial diameter > 45 mm; LAE group) and those witho

91 ber of AF episodes in the previous year, and left atrial diameter (adjusted hazard ratio, 0.35 [95% C

92 In atrial fibrillation (AF), left atrial diameter (LAD) and low voltage area (LVA) ar

93 In multivariable analysis, left atrial diameter (odds ratio, 1.111; 95% confidence

94 diastolic and systolic diameters and larger left atrial diameter (P<0.05).

95 rdless of MS status, as evidenced by greater left atrial diameter and left ventricular mass although

96 ears; mean CHA2DS2-VASc score was 4.1+/-1.4; left atrial diameter averaged 4.7+/-0.8 cm; and 48% had

97 P=0.015) scores as well as persistent AF and left atrial diameter were significant predictors for ERA

98 confidence interval, 2.070-7.143; P<0.001), left atrial diameter>/=50 mm (hazard ratio 2.083; 95% co

99 nts (18 women; mean age, 61+/-11 years; mean left atrial diameter, 43+/-5 mm) with paroxysmal (36 of

100 However, AF type, left atrial diameter, and especially ERAF are also signi

101 ug use, previous use of diuretics, increased left atrial diameter, increased left ventricular end-dia

102 s; and 1.15 (1.02-1.30) per 1 SD increase in left atrial diameter.

103 mm), severe basal LVOTO (70-120 mm Hg), and left atrial dilatation (44-57 mm).

104 astolic, longitudinal systolic function, and left atrial dilatation compared with asymptomatic patien

105 Left atrial dilatation in the population is more common

106 , LV hypertrophy, concentric remodeling, and left atrial dilatation when corrected for indices of AS

107 c dysfunction, left ventricular hypertrophy, left atrial dilatation, and interstitial fibrosis.

108 al left ventricular remodeling and/or severe left atrial dilation.

109 PO in MT1-MMP reduced expression reduced left atrial dimension (19%), LTBP-1 hydrolysis (40%), an

110 ydrolysis (18%), collagen content (60%), and left atrial dimension (19%; indicative of LV diastolic d

111 o [HR] per decade, 1.55; 95% CI, 1.11-2.15), left atrial dimension (HR per centimeter diameter, 1.43;

112 wall thickness, LV diastolic dimension, and left atrial dimension (P<0.01 for all; n=2392; mean age,

113 had associated cardiovascular disease, mean left atrial dimension was 46+/-6 mm, and median CHA2DS2-

114 age at diagnosis, female sex, and increased left atrial dimension.

115 al pathophysiology), cause and effect (i.e., left atrial dynamics impute disease events as consequenc

116 ft ventricular hypertrophy and diastolic and left atrial dysfunction.

117 s also exhibited a signi fi cant increase in left atrial ejection fraction at 2 months after gene del

118 Left ventricular adaptation was similar; left atrial ejection fraction improved by +3.17% (P < 0.

119 During left atrial electrogram mapping, including complex fract

120 Left ventricular end-diastolic and left atrial end-systolic volumes increased by 3.63 ml/m(

121 Eligibility also required either left atrial enlargement (>/=4.4 cm or volume >/=58 mL) o

122 remodeling (34%) and hypertrophy (43%), and left atrial enlargement (53%).

123 Controversy exists regarding whether left atrial enlargement (LAE) is a predictor of stroke/s

124 ive physiology, characterized by progressive left atrial enlargement and diastolic dysfunction with p

125 d age, female sex, greater right atrial than left atrial enlargement and lower systolic pulmonary art

126 Mutant mice had left atrial enlargement and Micu2(-/-) cardiomyocytes ha

127 traditionally have been used as markers for left atrial enlargement, and both have been associated w

128 alls, decreased left ventricular dimensions, left atrial enlargement, and hyperdynamic left ventricul

129 , including left ventricular hypertrophy and left atrial enlargement, in addition to pulmonary hypert

130 cular hypertrophy and a higher prevalence of left atrial enlargement.

131 r hypercontractility, diastolic dysfunction, left-atrial enlargement and left ventricular fibrosis, a

132 Our goal is to find and characterize left atrial-expressed transcripts in the chromosome 4q25

133 Left atrial fibrosis is prominent in patients with atria

134 sted overall hazard ratio per 1% increase in left atrial fibrosis was 1.06 (95% CI, 1.03-1.08; P < .0

135 ent, were predominantly found in the lateral left atrial free wall, and likely acted as drivers.

136 In goat left atrial free walls, most of the breakthroughs can be

137 Left atrial global peak atrial longitudinal strain and p

138 , elevated post-bypass Fontan (>20 mm Hg) or left atrial (>13 mm Hg) pressures, prolonged chest tube

139 sure was </=15 mm Hg in 54%, indicating that left atrial hypertension was absent in a majority of pat

140 Moreover, left atrial hypertrophy led to AT proliferation, with a

141 nd the development of interstitial fibrosis, left atrial hypertrophy, and pulmonary edema.

142 ntricular (LV) dysfunction, ischemic MR, and left atrial infarction (LAI); and 2) to analyze how LA r

143 n FEV1/FVC ratio was associated with smaller left atrial internal dimension (beta = -0.038 cm per SD

144 luded pulmonary vein isolation in 50 (100%), left atrial isthmus line in 47 (94%), anterior line in 4

145 imaging was used for the characterization of left atrial (LA) and left atrial appendage (LAA) flow dy

146 Echocardiography, left atrial (LA) and Swan-Ganz catheters were used for m

147 Left atrial (LA) compliance and contractility influence

148 The value of left atrial (LA) diameter, volume, and strain to risk st

149 ht to determine the prognostic importance of left atrial (LA) dilation in patients with type 2 diabet

150 Although left atrial (LA) dysfunction is common in heart failure

151 We sought whether left atrial (LA) electromechanical conduction time (EMT)

152 agnetic resonance (CMR) signal intensity and left atrial (LA) endocardial voltage after LA ablation.

153 oncentric left ventricular (LV) hypertrophy, left atrial (LA) enlargement and dysfunction, and LV dia

154 Although left atrial (LA) enlargement is a recognized risk factor

155 Left atrial (LA) enlargement is associated with adverse

156 Severity of left atrial (LA) fibrosis is a strong predictor of atria

157 Left atrial (LA) function is tightly linked to several c

158 , little is known about the impact of VNS on left atrial (LA) function.

159 Data on the clinical use of left atrial (LA) hemodynamic monitoring during MitraClip

160 Left atrial (LA) low voltage areas were semiquantitative

161 Left atrial (LA) remodeling after an acute myocardial in

162 Left atrial (LA) remodeling is an important underlying s

163 Left atrial (LA) size is a marker of diastolic function

164 Left atrial (LA) size is an established marker of risk f

165 Purpose To determine whether left atrial (LA) strain quantification with cardiac magn

166 Atrial fibrillation (AF) is associated with left atrial (LA) structural and functional changes.

167 Left atrial (LA) structure and function are altered in m

168 le describing factors influencing changes in left atrial (LA) structure.

169 associated with significant abnormalities of left atrial (LA) systolic and diastolic function.

170 s were stratified into 2 groups according to left atrial (LA) volume index >/=35 mL/m(2).

171 sought to (1) identify reference values for left atrial (LA) volumes and phasic function indices by

172 inium enhancement MRI (LGE-MRI) can identify left atrial (LA) wall structural remodeling (SRM) and st

173 Prior studies have demonstrated regional left atrial late gadolinium enhancement (LGE) heterogene

174 eems to be sufficient to treat patients with left atrial low voltage < 10%.

175 igh and low CF values can be observed during left atrial mapping and ablation.

176 CF during point-by-point left atrial mapping was assessed in 30 patients undergoi

177 During left atrial mapping, optimal contact parameters minimizi

178 ickness and image intensity ratio defined as left atrial myocardial LGE signal intensity divided by t

179 Left atrial myocardium of patients with atrial fibrillat

180 Samples of human left atrial myocardium showed a positive correlation bet

181 clinical in vivo study, we demonstrate that left atrial myocardium with increased gadolinium uptake

182 In vitro I-1c gene transfer in isolated left atrial myocytes from both pigs and rats increased c

183 We report an 11-year- old boy with left atrial myxoma and multiple cerebral oncotic aneurys

184 ervous system metastases associated with the left atrial myxoma.

185 rial triggers and substrate most commonly of left atrial origin.

186 l voltage amplitude (right atrial, P=0.0005; left atrial, P=0.0001), slower conduction velocities (ri

187 conduction velocities (right atrial, P=0.02; left atrial, P=0.0002), and higher prevalence of electro

188 tudy was to test the hypothesis that reduced left atrial passive emptying function (LAPEF) as determi

189 clustering (i.e., commonality of underlying left atrial pathophysiology), cause and effect (i.e., le

190 Intraoperatively a small infected left atrial perforation was oversewn and a fistula to th

191 th was delivered to the left atrium, and the left atrial port was closed using an off-the-shelf nitin

192 e relationship between the esophagus and the left atrial posterior wall is variable, and the esophagu

193 +/- 44 mm Hg to 12 +/- 6 mm Hg; p = 0.007), left atrial pressure (29 +/- 11 mm Hg to 20 +/- 8 mm Hg;

194 systemic hypotension occurred with a fall in left atrial pressure and little change in left ventricul

195 evice is feasible, seems to be safe, reduces left atrial pressure during exercise, and could be a new

196 Absence of left atrial pressure elevation was based on combined hem

197 rt failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the ris

198 nd we describe the design of REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I),

199 ed trial of a device-based therapy to reduce left atrial pressure in HFpEF.

200 The REDUCe Elevated Left Atrial Pressure in Patients with Heart Failure (RED

201 REDUCE LAP-HF I (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure) was

202 Left atrial pressure increases at exercise with an avera

203 y was that a mechanical approach to reducing left atrial pressure might be effective in HFPEF.

204 nt device that allows shunting to reduce the left atrial pressure provides clinical and hemodynamic b

205 EF is complex but characterised by increased left atrial pressure, especially during exertion, which

206 Elevated left atrial pressure, particularly during exercise, is a

207 a heterogeneous clinical syndrome, elevated left atrial pressure-either at rest or with exertion-is

208 Two of 27 pigs did not undergo left atrial procedures and were injected with microembol

209 reath-hold to the atrioventricular junction, left atrial pulmonary vein junction, and freewall left v

210 The pulmonary vein-left atrial (PV-LA) junction is key in pathogenesis of A

211 Balloon and tissue temperatures (left atrial-PV junction, phrenic nerve, and internal eso

212 sus -6.5 [-46.2 to 28.9] degrees C, P<0.001; left atrial-PV junction: -6.7 [-20.0 to 21.4] versus 15.

213 procedural rivaroxaban administration during left atrial radiofrequency ablation (RFA) in comparison

214 on in MR with favorable left ventricular and left atrial reverse remodeling.

215 out the use of rivaroxaban in the setting of left atrial RFA procedures are lacking.

216 ents (mean age, 63+/-10 years) who underwent left atrial RFA procedures between February 2012 and May

217 In patients undergoing left atrial RFA, continuous periprocedural rivaroxaban u

218 antly associated with gene expression in 329 left atrial samples.

219 among patients, most commonly involving the left atrial septum (32/43; 74.4%).

220 ventricular ejection fraction (P = 0.67), or left atrial size (P = 0.43) after SAVR on echocardiograp

221 ), C-reactive protein levels (P<0.0001), and left atrial size (P=0.03).

222 he author reviews the methods used to assess left atrial size and function and discusses their role i

223 The author examines the ability of left atrial size and function to predict cardiovascular

224 g clinical predictors with the evaluation of left atrial size by echocardiography serving as the sole

225 and 10 cm/s, respectively), whereas E/e' and left atrial size demonstrated good agreement with guidel

226 N-terminal pro-brain natriuretic peptide and left atrial size suggest that the angiotensin receptor n

227 ptide levels, C-reactive protein levels, and left atrial size were associated with arrhythmia recurre

228 (tissue Doppler imaging [TDI] e', E/e', and left atrial size) with concomitant N-terminal pro-brain

229 alysis, only RV fractional area change, age, left atrial size, diabetes, and previous coronary artery

230 mated glomerular filtration rate, and larger left atrial size, left ventricular volume, and mass.

231 imary outcome after correction for age, sex, left atrial size, nonsustained ventricular tachycardia,

232 After adjusting for age, sex, and left atrial size, standard ablation was predictive of re

233 Persistent AF for <1 year, a smaller left atrial size, substrates with higher mean voltages a

234 dex, left ventricular ejection fraction, and left atrial size.

235 The intensity of left atrial spontaneous echo contrast (LASEC) by transes

236 Included were 285 left atrial static ablations, 247 with additional impeda

237 s (namely segmental left ventricular strain, left atrial strain, and right ventricular strain) are al

238 The state of combined left atrial structural and functional features (i.e., sy

239 Individual left atrial structural and functional features do not de

240 Left atrial structure and function can be used to reflec

241 After ablation of 17 +/- 10% of the left atrial surface and 18 months of follow-up, the atri

242 atients of group I with low amount (< 10% of left atrial surface area) of atrial low voltage.

243 Basket electrodes were within 1 cm of 54% of left atrial surface area, and a mean of 31 electrodes pe

244 A trend toward a higher incidence of left atrial tachycardia occurrence in the wide antral ci

245 t an underlying atrial cardiopathy may cause left atrial thromboembolism in the absence of recognized

246 rs of stroke, CHADS2 score and CHA2DS2-Vasc, left atrial thrombus (LAT), the five-grades of LASEC and

247 Right and left atrial tissue was obtained from patients with parox

248 lude axial flow pumps, such as Impella((R)); left atrial to femoral artery bypass pumps, specifically

249 e using radiofrequency ablation demonstrated left atrial to pulmonary vein reconduction.

250 We sought to characterize the left atrial transcriptome in human AF to distinguish cha

251 s a disease of variable interactions between left atrial triggers and substrate most commonly of left

252 [apnea-hypopnea index <5]), right atrial and left atrial voltage distribution, conduction velocities,

253 diastolic volume (139 to 107 mL; P=0.03) and left atrial volume (118 to 85 mL; P=0.04).

254 astolic dysfunction (P = .003) and increased left atrial volume (57 +/- 11 vs 46 +/- 12 mL/m(2), P =

255 Left atrial volume (LAV) is an important marker of heart

256 ventricular end-systolic volume (LVESV) and left atrial volume (LAV), are unknown.

257 amber pacemaker implantation, independent of left atrial volume (LAV).

258 Global ECV significantly correlated with left atrial volume (P = .002) and with the grade of dias

259 ' z-score (r = 0.55, p = 0.003), and indexed left atrial volume (r = 0.56, p = 0.001).

260 tion rate was higher (51.9%/y) in those with left atrial volume above the median value of 73.5 mL.

261 Decrease in left atrial volume at follow-up was associated with a lo

262 Reduction in left atrial volume at follow-up was associated with a lo

263 ta are sufficient to recommend evaluation of left atrial volume in certain populations, and although

264 elocities >2, RAP >10 mm Hg, sPAP >40 mm Hg, left atrial volume index >33 ml/m(2), ratio of mitral in

265 Left atrial volume index (24.0+/-3.6 versus 26.7+/-6.9 m

266 versus 268+/-62 ms; P<0.0001), and increased left atrial volume index (49+/-18 versus 42+/-15 mL/m2;

267 ricular global longitudinal strain (GLS) and left atrial volume index (LAVI) have been recently propo

268 interval, 1.04-1.43; P=0.015) and increased left atrial volume index (LAVi; adjusted hazard ratio/un

269 end-systolic volume index (r=0.62, P<0.01), left atrial volume index (r=0.41, P<0.05) but lower left

270 ing mitral inflow velocities, RAP, sPAP, and left atrial volume index was 90% accurate in distinguish

271 ft ventricular end-systolic volume index and left atrial volume index were independent predictors of

272 d diastolic function (based on e', E/e', and left atrial volume index) were each independently and ad

273 sis, LV mass index, relative wall thickness, left atrial volume index, and deceleration time were sti

274 rate, older age, elevated creatinine, larger left atrial volume index, and larger left ventricular en

275 e, including carotid intima-media thickness, left atrial volume index, monocyte count and serum YKL-4

276 with diastolic dysfunction (E/e') and 5 with left atrial volume index.

277 with greater left ventricular (LV) mass and left atrial volume indexed to height(2.7) in both men an

278 nal pro B-type natriuretic peptide; however, left atrial volume reduction varied by baseline level of

279 atriuretic peptide) and secondary (change in left atrial volume) end points.

280 sue inhibitor of matrix metalloproteinase 1, left atrial volume), myocardial stretch (NT-proBNP [N-te

281 (medial E/e', 16; deceleration time, 185 ms; left atrial volume, 44 mL/m(2)) and increased arterial l

282 V end-systolic volume, LV ejection fraction, left atrial volume, and LV dyssynchrony at 1-year in CRT

283 volume, left ventricular ejection fraction, left atrial volume, and LV dyssynchrony.

284 analysis identified age, diabetes mellitus, left atrial volume, and mean gradient as independent pre

285 s, mass, maximal wall thickness, morphology, left atrial volume, and mitral valve leaflet lengths (al

286 ection fraction, relative wall thickness and left atrial volume, and worse New York Heart Association

287 sed left ventricular end-diastolic pressure, left atrial volume, N-terminal propeptide of brain natri

288 and <17.8 ng/mL galectin 3) had reduction in left atrial volume, those above median did not.

289 tive wall and septal thickness, LV mass, and left atrial volume.

290 al pro B-type natriuretic peptide, E/E', and left atrial volume.

291 , indexed left ventricular mass, and indexed left atrial volume.

292 ness, and hypertrophy patterns and function; left atrial volume; and aortic root diameter.

293 1 +/- 36 ml to 122 +/- 30 ml; p < 0.001) and left atrial volumes (106 +/- 36 ml to 69 +/- 24 ml; p <

294 systolic circumferential strain (PSCS), and left atrial volumes and function, whereas phosphorus-31

295 ventricular (LV) systolic function, LV mass, left atrial volumes, and blood pressure response did not

296 roduct were attenuated when adjusted for CMR left atrial volumes.

297 ciation was attenuated when adjusted for CMR left atrial volumes.

298 sis, clustered by patient, and adjusting for left atrial wall thickness, conduction velocity was asso

299 monary vein (PV) regions and inferoposterior left atrial wall.

300 The left atrial was accessed, and the port was closed succes